Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-066914
Filing Date
2025-05-08
Accepted
2025-05-08 16:05:38
Documents
71
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ntla-20250331.htm   iXBRL 10-Q 2325731
2 EX-31.1 ntla-ex31_1.htm EX-31.1 14917
3 EX-31.2 ntla-ex31_2.htm EX-31.2 14937
4 EX-32.1 ntla-ex32_1.htm EX-32.1 9657
  Complete submission text file 0000950170-25-066914.txt   9187995

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ntla-20250331.xsd EX-101.SCH 1241221
74 EXTRACTED XBRL INSTANCE DOCUMENT ntla-20250331_htm.xml XML 1631243
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37766 | Film No.: 25925942
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)